Novel injectable drug for faster healing of broken bones moves closer to clinical trials

One in three adults aged 60 and over suffering from a hip fracture dies within one year. Now, a Purdue University-affiliated startup is moving closer to the start of clinical trials for a novel injectable drug that is targeted to heal broken bones faster and strengthen weak bones.

The Purdue University discovered drug, NOV004, from Novosteo Inc. is unique in that it concentrates at the fracture site while reducing exposure to the rest of the body.

Novosteo, the startup developing the drug, was co-founded by father-son team Philip S. Low, the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, and Stewart A. Low, the company's CSO and Visiting Scholar in Purdue's Department of Chemistry. The treatment was developed in the Purdue laboratory of Low in the Purdue Institute of Drug Discovery. Currently there are 288 clinical trials performed or in process using Purdue-developed medical treatments at 4,841 sites across the globe.

Scott Salka, who recently joined the startup as executive chair, will use his 28 years of experience as a biotechnology entrepreneur to help Novosteo move its innovations from the laboratory to clinical trials and ultimately in to the hands of doctors and patients.

We have been working on some amazing science with people truly dedicated to making a difference in reducing the mortality and improving the quality of life for our aging population. We have completed preclinical studies with NOV004 and are looking to take it to clinical trials later this year."

Scott Salka, executive chair, Novosteo

As CEO, Salka has successfully led efforts to advance novel drugs through preclinical and early clinical development, most recently at publicly traded Ampliphi, now Armata NYSE: ARMP. Prior to that he founded and served as CEO for both Ambit Biosciences, acquired by Daiichi Sankyo OTC: DSNKY, and Rakuten Medical.

Novosteo is already looking at the future use of the injectable-targeted drug for other applications, including dental implants, head and facial fractures, and hip and knee replacements. In addition, Novosteo has a pipeline of drugs for treating an array of musculoskeletal maladies. Salka will present some of the technology at Biocom's Global Life Science Partnering Conference this month in La Jolla, California.

Novosteo's technology is licensed through the Purdue Research Foundation Office of Technology Commercialization. The company also received entrepreneurial support from Purdue Foundry, an entrepreneurship and commercialization hub in Discovery Park District's Convergence Center for Innovation and Collaboration where startups, entrepreneurs, innovators and companies can collaborate with Purdue to address global challenges in health, sustainability, IT and space.

The Purdue Institute of Drug Discovery is situated near the district, a $1 billion-plus long-term enterprise to support a transformational center of innovation on the western edge of the Purdue University campus. The district already includes a public airport with a 7,000-foot runway, and partnerships international companies including Rolls-Royce, Schweitzer Engineering Laboratories and Saab. Visit Discovery Park District.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Researchers aim to exploit DNA mutations in the treatment of blood and bone marrow cancers